Ledger.Open graph →
SEC Form D · Amendment · filed January 13, 2025

Aviceda Therapeutics, Inc

Offering
$207.5M
Sold
$75.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
CAMBRIDGE, MA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (10)

Mohamed Genead · Cambridge, MAExec · DirectorErin Lavelle · Cambridge, MADirectorDerek Kunimoto · Cambridge, MAExecDavid Callanan · Cambridge, MAExecDavid Guyer · Cambridge, MADirectorNancy Thomason · Cambridge, MADirectorMichael Tolentino · Cambridge, MAExec · DirectorJay Woods · Cambridge, MADirectorTarek Hassan · Cambridge, MAExecChristoph Adams · Cambridge, MADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗